Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase  by Aakerlund, Lars et al.
Volume 260, number 1, 73-78 FEB 08011 January 1990 
Y, receptors for neuropeptide Y are coupled to mobilization of 
intracellular calcium and inhibition of adenylate cyclase 
Lars Aakerlund, Ulrik Gether, Jannie Fuhlendorff, Thue W. Schwartz and Ole Thastrup” 
Laboratory for Molecular Endocrinology, University Department of Clinical Chemistry’s Rigshospitalet and “Thrombosis Group, 
Copenhagen Science Park Symbion and University Department of Clinical Chemistry’s Rigshospitalet, Copenhagen, Denmark 
Received 16 October 1989; revised version received 22 November 1989 
Two types of binding sites have previously been described for neuropeptide Y (NPY), called Y, and Y2 receptors. The intracellular events following 
Y, receptor activation was studied in the human neuroblastoma cell line SK-N-MC. Both NPY and the specific Y, receptor &and, [I.&r,Prdq]- 
NPY, caused a rapid and transient increase in the concentration of free calcium in the cytoplasm as measured by the fluorescent probe, Fura-2. 
The effect of both peptides was independent of extracellular calcium as addition of EGTA or manganese neither changed the size nor the shape 
of the calcium response. The calcium response to NPY was abolished by pretreatment with thapsigargin, which can selectively deplete a calcium 
store in the endoplasmic reticulum. Y, receptor stimulation, by both NPY and [LeuJ1,Prd4]NPY, also inhibited the forskolin-stimulated CAMP 
production with an EC,, of 3.5 nM. There was a close relation between the receptor binding and the cellular effects as half-maximal displacement 
of PZsI-TylJ6]monoiodoNPY from the receptor was obtained with 2.1 nM NPY. The Y,-specific ligand NPY(16-36)peptide had no effect on either 
intracellular calcium or CAMP levels in the SK-N-MC cells. It is concluded that Y, receptor stimulation is associated with both mobilization of 
intracellular calcium and inhibition of adenylate cyclase activity. 
Peptide receptor; Calcium intracellular; Fura-2; CAMP; pH, intracellular 
1. INTRODUCTION 
Neuropeptide Y (NPY) is a 36 amino acid regulatory 
peptide which is widely distributed throughout the cen- 
tral and peripheral nervous systems [l-3]. The primary 
structure of NPY is evolutionarily well conserved [1,4] 
and the peptide belongs together with peptide YY and 
pancreatic polypeptide to the so-called pancreatic 
polypeptide-fold peptide family. This family of pep- 
tides is characterized by a common tertiary structure 
which is stable even in dilute aqueous solutions [5]. 
In the peripheral nervous system, NPY is often 
found to colocalize with noradrenaline in the sym- 
pathetic nerve terminals. NPY is released together with 
noradrenaline and acts together with noradrenaline in 
regulation of the vascular tone. The neurophysiology 
of NPY has recently been reviewed in a symposium 
volume [6]. 
It was recognized early that NPY receptors are coupl- 
ed to G-proteins [7,8]. However, a rather diffuse pic- 
ture of the secondary messenger systems for NPY has 
since appeared [9]. NPY has been shown to inhibit 
adenylate cyclase in several tissues and some cell lines 
[ 10-161. Mobilization of intracellular calcium has also 
been associated with NPY in human erythroleukemia 
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cells and in cultured neurons from rat dorsal root 
ganglia [16,17]; whereas this effect was not found in 
cultured vascular smooth muscle cells from the rabbit 
lung artery [15]. Furthermore, NPY has been shown to 
be able to inhibit voltage-sensitive calcium channels 
]181. 
Recently, two different types of NPY receptors, call- 
ed Yi and Yz, have been defined on the basis of their 
different binding profile for long C-terminal fragments 
of NPY and of the new, specific Yi receptor ligand 
[Leu3’,Pro34]NPY [5,19-221. Presently, we have 
studied the second messengers coupled to the activation 
of the Yi type receptor in a human neuroblastoma cell 
line (SK-N-MC), which only expresses Yr receptors. It 
is found that Yi receptor activation leads both to 
mobilization of intracellular calcium and to inhibition 
of adenylate cyclase. 
2. MATERIALS AND METHODS 
2.1. Peptides 
Porcine NPY and [Leu31,Pro34]NPY were synthesized by 
automatic stepwise solid phase synthesis on an Applied Biosystems 
model 430A peptide synthesizer, as previously described in detail 
[22]. The peptides were quantified and amino acid composition con- 
trolled by amino acid analysis according to [22]. NPY(16-36) was ob- 
tained from Peninsula Laboratories, St. Helens, England. The 
peptides were stored at -20°C in stock solutions of 1.0 mM in 
IO-’ M acetic acid. The peptides were added in 1% (v/v) to the cell 
suspensions from adequate solutions in Hepes buffer. 
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2.2. Cell culture 
SK-N-MC human neuroblastoma cells [23] were kindly provided 
by Drs June Biedler and Barbara A. Spengler, Sloan Kettering 
Memorial Institute, NY, USA. The cells were cultured in 800 ml 
culture flasks (Costar, Cambridge, MA, USA) in a 1: 1 mixture of 
Ham F12 medium and Dutbecco’s modified Eagles medium with 
10% fetal calf serum, 1% non-essential amino acids, 2 mM glutamin 
and penicillin/streptomycin (100 IU and 100 gg/ml, respectively), all 
purchased from Gibco, Uxbridge, England. 
2.3. Cytosolic free calcium concentration ([Cd”]& 
Confluent monolayer cultures of SK-N-MC cells were harvested 
3-7 days after seeding by washing with medium and gently scraping 
with a rubber policeman. The cells were centrifuged for 5 min at 
200 x g and resuspended in cell medium to a concentration of 3 x lo6 
cells/ml. Fura- acetoxymethyl ester (Molecular Probes, OR, USA) 
was added at a final concentration of 2.5 CM from a stock solution 
of 1 mM in dimethyl suifoxide (DMSO). The cells were incubated for 
30 min in the dark at room temperature. After centrifugation (200 x 
g for 5 min), the cells were resuspended at a density of 2.0 x lo6 
cells/ml in 3 ml Hepes buffer (145 mM NaCl, 5 mM KCI, 1 mM 
MgS04 and 10 mM glucose in 10 mM Hepes 
(~-2-hydroxyethylpiperazine-~I-2-ethanesu~fonic a id), with 
150 mg/l bovine serum albumin, adjusted to pH 7.4). The cells were 
used within 30 min and kept in suspension by gentle magnetic stirring 
at 37’C. The Fura- fluorescence was measured in a Hitachi Spec- 
trofluorometer (F-2000) with a monochromatic setting of 340 nm ex- 
citation and 500 nm emission (slit = 10 nM). Calculation of 
cytoplasmic calcium concentrations were done according to 
Grynkiewicz et al. [24] using the formula: 
[Ca2+]i = K(F - F&/(F mai -n 
K = 224 nM represents the apparent dissociation constant for 
Fura-2-Ca’+. Fmax, const~tuti~ the fluorescence of Fura- when 
saturated with Ca*+, was determined by adding 2.5 FM ionomycin 
(Sigma) in the presence of 1 mM extracellular Ca”. Fmin, 
fluorescence of Fura- in absence of Ca’+, was measured by chelating 
external Ca2+ with 10 mM EGTA following the addition of 
ionomycin. F, F,, an d&jr, were corrected for extracellularly present 
Fura- by subtra~ing corresponding fluorescence values determined 
in the supernatant of centrifuged (200 x g for 10 min) cell 
suspension. 
2.4. Cytosolic pH measurements 
SK-N-MC cells in suspension (density 3 x lo6 cells/ml) were loaded 
with the pH-sensitive fluorescent probe, 2,7-biscarboxyethyI-5(6)- 
carboxyfluorescein (BCECF) together with Fura- under conditions 
as described above. pH and [Ca’+]t could then be measured 
simultaneously by alternating the monochromatic setting between 
340 nM excitation/500 nM emission for Fura- measurements and 
495 nM excitation/530 nM emission for BCECF measurements. At 
the end of each experiment, the protonophore nigericine (Sigma) was 
added in a final concentration of 5 pM in order to equalize pHi and 
pH,, after pH was determined as a function of fluorescence by 
measurement of corresponding pH and fluorescence values. 
2.5. Binding ex~rime~ts 
Binding experiments were performed as previously described in 
detail [18-211. Shortly, SK-N-MC cells (1.2 x IO’) were grown in 
Petri wells, 6-well culture plates (Costar, Cambridge, MA, USA) for 
l-2 days before incubation at 37°C for 60 min with 25 pM [1251- 
Tyr36]monoiodoNPY and cold peptide as indicated. All determina- 
tions in the experiments were done in triphcate. 
2.6. CAMP measurements 
The cells were harvested as described above and resuspended in 
Hepes buffer at a cell density of 2.5 x lo6 cells/ml and divided into 
vials containing 1 ml of ceh suspension each. The phosphodiesterase 
inhibitor 3-jsobutyI-l-methylxanthine (IBMX) (Sigma) was added to 
a concentration of 0.5 mM. The ceils were preincubated for 10 min 
at 37°C before incubation for 20 min with 5 /rM forskolin (Sigma) 
and peptides as indicated. The incubations were terminated and the 
cells extracted by the addition of 0.2 ml 20% perchloric acid and 
vigorous vortexing, followed by a 15min incubation on ice and cen- 
trifugation for 15 min at 2050 x g. The amount of generated CAMP 
was measured in the supernatants after SO-fold dilution in 0.1 M 
acetate buffer by using Amersham’s single range CAMP assay kit, 
RPA.508. 
3. RESULTS 
In SK-N-MC cells, NPY (100 nM) caused a rapid, 
transient elevation of [Ca’+]i from a resting level bet- 
ween 90 and 100 nM to a peak value of 205 nM + 
8.7 nM (mean f SE, n = 15) (fig.1). The signal return- 
ed to baseline within 60 s (fig. 1). The specific YI recep- 
tor agonist, [Leu31,Pro34]NPY similarly raised [Ca’+]i 
with 107 nM + 15 nM (mean t SE, n = 4) (fig.l), 
whereas stimulation of the cells with the YZ specific 
ligand, NPY(16-36) peptide, caused no measurable in- 
creases in the Fura- fluorescence (fig.1). 
The effect of NPY was found to be independent of 
extracellular calcium. It thus appeared that removal of 
extra~ellular calcium (addition of 1 mM EGTA) neither 
changed the shape nor the size of the [Ca”]i response 
to NPY or to [Leu3’,Pro34]NPY; the increase during 
NPY stimulation in the absence of extracellular calcium 
was 117 nM * 11 nM (mean & SE, n = 13) and during 
[Leu3’,Pro~]NPY stimulation 90 nM t 14 nM 
(mean f SE, n = 3) (fig.l). Furthermore, when using 
manganese (Mn2+) as a marker for Ca2’ influx [25], we 
were not able to detect any Mn2+-induced quenching of 
the Fura- signal. 
Stimulation of cholinergic, muscarinic receptors in- 
duced a [Ca’+]i signal that was different from the NPY 
response. It was thus found that optimal concentra- 
tions (1OOsM) of carbacholine (CCh) only induced a 
minor [Ca2+]i rise (47 nM + 3 nM, mean -+ SE, n = 
IO), and that [Ca2+]i stayed elevated in the presence of 
extracellular calcium for an extended period (fig.2, up- 
per panel). On removal of external Ca2+, the CCh 
signal became transient (fig.2, lower panel). This pat- 
tern of events corresponds to an initial discharge of in- 
tracellular stored Ca2+ followed by an influx from the 
external medium. Pretreatment with CCh did not 
diminish the [Ca2+]i response to NPY (fig.2). Although 
the NPY response following CCh appears larger than 
the response to NPY alone, this was not a general 
observation. 
In order to characterize the intracellular Ca’+ pool 
sensitive to NPY, we used the Ca2’-mobilizing agent, 
thapsigargin. This agent releases Ca2+ from a discrete 
intracellular pool by a direct, highly selective inhibition 
of Ca2’-activated ATPase, the presumptive Ca2+ 
pump, situated in the membranes of the endoplasmic 
reticulum 1261. Taking into account that thapsigargin 
easily permeates the plasma membrane, this compound 
can be used to study intracellular Ca2+ release in intact 
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Fig.1. Effect of NPY, NPY(l6-36) peptide, and [Leu3’,Pro34]NPY on [Ca”]i in human SK-N-MC cells. The experiments were performed with 
100 nM of the peptides on cells in suspension; in the left panels in the presence of 1 mM Ca2+ and in the right panels without calcium and in 
the presence 1 of 
[Ca 8+& 
I& 
400 
300 
0 
ECa Vi 
IlM 
400 
300 
200 
100 
0 
1 mM of EGTA. The calcium chromophore Fura- was used and the calculated cytoplasmic free calcium concentration is plotted 
against time. The traces shown are representative of 3-15 experiments. 
, 
t 
0 
CCh 
Cag+free 
50 100 150 200 i 
Time (set) 
-$ 
:60 
400 -- 
04 
0 100 200 305 4 
Time (set) 
Fig.2. The effect of CCh and NPY on [Ca’+]i of SK-N-MC cells in Fig.3. Effect of NPY and thapsigargin (Tg) on [Ca”]i of SK-N-MC 
suspension in the presence and absence of extracellular calcium. The cells in absence of extracellular calcium. The upper panel shows the 
upper panel shows the response to 0.1 mM CCh followed by 100 nM 
NPY in the presence of 1 mM Ca** and the lower panel in the 
stimulation with 50 nM Tg followed by 100 nM NPY; the lower 
panel, the stimulation with NPY followed by Tg. In the insert, the 
presence of 1 mM EGTA. Calculated calcium concentration is peak increase in cytoplasmic calcium concentration following Tg 
plotted against time. The traces shown are representative of 4 alone (50 nM) and with prior stimulation with 100 nM NPY (* P < 
experiments. 0.05, n = 3-4, t-test) is shown. 
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cells by a mechanism not involving production of in- 
ositol polyphosphates or activation of protein kinase C 
[27,28]. In the presence of extracellular Ca2+, thap- 
sigargin raised [Ca2’]i to a new elevated steady state 
level (data not shown); on removal of external Ca2+, 
the thapsigargin signal became transient (fig.3, upper 
panel). NPY given shortly before thapsigargin 
significantly reduced this rise (fig.3, lower panel). The 
reverse administration of the two agonists showed that 
thapsigargin completely abolished the response to NPY 
(fig.3, upper panel), indicating that the stores from 
which NPY mobilizes calcium in the SK-N-MC cells are 
included in the intracellular stores that are sensitive to 
thapsigargin. 
NPY and [Leu31,Pro34]NPY also potently attenuated 
the forskolin-stimulated accumulation of CAMP 
(fig.4A), whereas the NPY(16-36) peptide had no 
detectable effect on the accumulation of CAMP in 
agreement with the binding properties of the Yr recep- 
tor found on these cells. The inhibition of the CAMP 
accumulation was dose dependent with an EC50 of 
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of the indicated peptides. Data are expressed as percent of maximal 
accumulated CAMP following 5 CM forskolin in 20-min incubations 
(mean f SE of 6-9 determinations in 3 different experiments). 
Maximal accumulated CAMP varied between 223 pmol/106 cells and 
381 pmol/106 cells. (B) Dose response of the effect of NPY. Data are 
expressed as percent of the maximal inhibitory effect (10m7 M NPY) 
(mean f SE of 6 determinations in 2 different experiments). (C) 
Inhibition of [‘2s1-Tyr36]monoiodoNPY binding by NPY to the SK- 
N-MC cells (n = 13). 
3.5 nM (fig.4B). Probably the attenuation of the 
CAMP accumulation is due to inhibition of adenylate 
cyclase rather than to stimulation of the 
phosphodiesterase, as the experiments were performed 
in the presence of the CAMP-phosphodiesterase in- 
hibitor IBMX. A close relation between the receptor 
binding and the cellular effects was found as NPY 
displaced [1251-Tyr36]monoiodoNPY bound to the SK- 
N-MC cells with a half-maximal concentration of 
2.1 nM (fig.4C). 
To exclude that the observed rise in [Ca2+]i was 
secondary to a fall in CAMP level, the cells were 
stimulated with 10 pM forskolin 3 min prior to the 
stimulation with NPY. In the present study, forskolin 
raised the intracellular level of CAMP la-fold above the 
basal level. Forskolin did not influence [Ca2+]i tself, 
nor did it alter the response to NPY. In a paired experi- 
ment, NPY raised [Ca2+]i to 131 nM + 13 nM (n = 3) 
above the basal level in cells pretreated with forskolin, 
compared to 140 nM + 4 nM (n = 3) in untreated cells. 
Some receptors which are linked to an inhibition of 
adenylate cyclase also stimulate the Na+/H+ exchange, 
thereby elevating the intracellular pH [29,30]. NPY did 
not elevate the intracellular pH, as assessed by the pH- 
sensitive probe BCECF. On the contrary, NPY slightly, 
but significantly lowered the pH of the SK-N-MC cells 
0.021 f 0.008 (n = 10, P < 0.02, t-test). The basal pH 
level was 7.45 + 0.02 (n = 10). The small decrease in 
pH may be secondary to the rise in [Ca2’] [31] as the 
calcium ionophore ionomycin lowered the intracellular 
pH by 0.073 + 0.009 (n = 10, P c 0.001, t-test). 
4. DISCUSSION 
NPY receptors have been both physiologically [19] 
and biochemically [20-221 divided into two types (Yi 
and Y2). The Yi receptor appears in most species and 
tissues to be the major postsynaptic receptor which is 
responsible for the vasoconstrictory action of NPY. By 
use of a human neuroblastoma cell line (SK-N-MC), 
which only expresses Yi type receptors for NPY 
[20-221, and by using a newly characterized specific 
ligand for this receptor type, we find that stimulation 
of Yr receptors is associated both with an inhibition of 
adenylate cyclase activity and with an increase in 
[Ca2+]i. The latter caused by mobilization of calcium 
from the thapsigargin depletable store, conceivably the 
endoplasmic reticulum. 
NPY-induced mobilization of intracellular calcium 
has previously been shown in human erythroleukemia 
cells (HEL) and in cultured neurons from dorsal root 
ganglia of rats (DRG) [16,17]. In these cases, the NPY 
receptor type was not characterized. However, in the 
HEL cells, the calcium response was similar to the 
response found in the SK-N-MC cells as it was tran- 
sient, independent of extracellular calcium and combin- 
ed with an inhibition of CAMP accumulation [16]. 
76 
Volume 260, number 1 FEBS LETTERS January 1990 
Thus, the NPY receptor on the HEL cells is probably 
also of the Yi type. 
The mechanism by which calcium is mobilized by 
NPY is not known but at least it seems to involve a GO 
or Gi-like protein [ 16,171. Whether this coupling to a 
G-protein leads to activation of phospholipase C and 
generation of inositol polyphosphates is uncertain. In 
the HEL cells, no increase in phosphoinositide turnover 
could be observed following stimulation with NPY and 
following activation of LYZ receptors [16,32]. In addi- 
tion, the monophasic calcium response to NPY differs 
from the classical biphasic response observed following 
stimulation of receptors coupled to phosphoinositide 
breakdown as seen, e.g. following the activation of 
muscarinic receptors [28] (fig.2). The apparent inability 
of NPY to induce Ca2+ influx could be explained by a 
lacking generation of inositol polyphosphates. Inositol 
1,3,4,5tetrakisphosphate (Ins 1,3,4,5-P4) together with 
Ins 1,4,5-P3 has thus been proposed to be involved in 
the regulation of Ca2+ entry (for review see [33]). Thap- 
sigargin, however, induced Ca2+ influx, even though it 
does not cause production of inositol polyphosphates 
[27]. The mechanism by which this occurs is believed to 
be emptying an Ins 1,4,5-P3-sensitive pool which then 
functions as a signal for Ca2+ entry [26,28]. It is temp- 
ting to speculate that this discrepancy is due to the fact 
that NPY is targeting a discrete pool in the endoplasmic 
reticulum that does not take part in the signalling of 
Cat+ entry. 
Inhibition of adenylate cyclase by NPY has been 
shown in a variety of cell types [lo-161 and, although 
no direct study has been performed, this effect appears 
also to be associated with the YZ receptor. In, e.g. the 
hippocampus, which only contains YZ type receptors 
[20], the inhibition of adenylate cyclase is very clear 
[lo]. Multiple receptors inhibiting adenylate cyclase ac- 
tivity are independently coupled to other cellular events 
including opening of K+ channels, inhibition of 
voltage-dependent calcium channels, Na+/H+ ex- 
change, and calcium mobilization (for review see [34]). 
Thus, it is likely to assume that the inhibition of 
adenylate cyclase and the calcium mobilization repre- 
sent two independent effects coupled to one receptor, 
i.e. the Yi receptor. Whether the YZ receptor subtype is 
associated with other cellular events than the inhibitory 
effect on adenylate cyclase remains to be determined. 
Possibly in some species it may be linked to voltage- 
sensitive calcium channels which are believed to 
mediate the prejunctional YZ receptor effect, i.e. inhibi- 
tion of noradrenaline and substance P release [6,18,19]. 
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